Applied Genetic Technologies Corp. (NASDAQ:AGTC) CFO Lawrence E. Bullock purchased 10,000 shares of Applied Genetic Technologies Corp. stock in a transaction on Monday, September 19th. The shares were acquired at an average cost of $8.75 per share, for a total transaction of $87,500.00. Following the purchase, the chief financial officer now owns 10,000 shares in the company, valued at $87,500. The acquisition was disclosed in a document filed with the SEC, which is available through this link.

Shares of Applied Genetic Technologies Corp. (NASDAQ:AGTC) opened at 8.89 on Thursday. The firm’s market capitalization is $160.49 million. Applied Genetic Technologies Corp. has a 12-month low of $8.50 and a 12-month high of $21.43. The stock’s 50 day moving average price is $13.10 and its 200-day moving average price is $14.73.

Applied Genetic Technologies Corp. (NASDAQ:AGTC) last posted its quarterly earnings results on Monday, September 12th. The company reported $0.15 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.07 by $0.08. The firm had revenue of $12.10 million for the quarter. Applied Genetic Technologies Corp. had a negative net margin of 2.92% and a negative return on equity of 1.34%. The company’s quarterly revenue was up 1604.2% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.48) EPS. On average, equities analysts expect that Applied Genetic Technologies Corp. will post ($0.61) EPS for the current year.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Numeric Investors LLC raised its position in Applied Genetic Technologies Corp. by 3.8% in the second quarter. Numeric Investors LLC now owns 720,969 shares of the company’s stock valued at $10,187,000 after buying an additional 26,670 shares during the period. Perceptive Advisors LLC raised its position in Applied Genetic Technologies Corp. by 1.3% in the second quarter. Perceptive Advisors LLC now owns 658,851 shares of the company’s stock valued at $9,309,000 after buying an additional 8,260 shares during the period. BlackRock Fund Advisors raised its position in Applied Genetic Technologies Corp. by 20.1% in the second quarter. BlackRock Fund Advisors now owns 555,987 shares of the company’s stock valued at $7,856,000 after buying an additional 93,015 shares during the period. Acadian Asset Management LLC raised its position in Applied Genetic Technologies Corp. by 68.3% in the second quarter. Acadian Asset Management LLC now owns 498,825 shares of the company’s stock valued at $7,047,000 after buying an additional 202,361 shares during the period. Finally, Vanguard Group Inc. raised its position in Applied Genetic Technologies Corp. by 7.7% in the second quarter. Vanguard Group Inc. now owns 445,962 shares of the company’s stock valued at $6,302,000 after buying an additional 31,762 shares during the period. Hedge funds and other institutional investors own 60.10% of the company’s stock.

AGTC has been the topic of a number of recent analyst reports. Stifel Nicolaus reduced their price target on Applied Genetic Technologies Corp. from $29.00 to $24.00 and set a “buy” rating on the stock in a research note on Tuesday, September 13th. Cantor Fitzgerald reissued a “buy” rating and set a $32.00 price target on shares of Applied Genetic Technologies Corp. in a research note on Wednesday, June 22nd. Wells Fargo & Co. lowered Applied Genetic Technologies Corp. from an “outperform” rating to a “market perform” rating in a research note on Tuesday, September 13th. Wedbush reduced their price target on Applied Genetic Technologies Corp. from $36.00 to $20.00 and set an “outperform” rating on the stock in a research note on Tuesday, September 13th. Finally, Janney Montgomery Scott lowered Applied Genetic Technologies Corp. from a “buy” rating to a “sell” rating and reduced their price target for the stock from $23.00 to $11.00 in a research note on Tuesday, September 13th. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $17.44.

About Applied Genetic Technologies Corp.

Applied Genetic Technologies Corp is a United States-based clinical stage biotechnology company. The Company develops gene therapy products for the treatment of inherited and acquired diseases. Its products are used to treat Alpha One Antitrypsin Deficiency (Alpha-1), a respiratory disease caused by deficiencies in the tissue protective protein alpha one antitrypsin; and Lebers congenital amaurosis, an inherited condition causing early blindness.

5 Day Chart for NASDAQ:AGTC

Receive News & Ratings for Applied Genetic Technologies Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Genetic Technologies Corp. and related companies with Analyst Ratings Network's FREE daily email newsletter.